Table 2: Knight-ADRC participants’ characteristics.
Data is shown as mean(SD) unless otherwise stated. Participants are divided by clinical diagnosis and amyloid status based on their CSF Aβ42/40 levels (Aβ+: <0.0673). Very mild AD dementia patients had a CDR=0.5 and mild AD dementia patients had a CDR≥1, both with AD as etiology. Other dementias group includes participants with CDR>0 with non-AD etiology. Only participants who progressed to CDR≥0.5 or CDR≥1 due to AD etiology were considered to progress.
| All (n=222) | CU− (n=84) | CU+ (n=98) | Very mild AD (n=24) | AD dementia (n=9) | Other dementias (n=7) | |
|---|---|---|---|---|---|---|
| Age, years | 71.2 (7.7) | 67.6 (7.2) | 73.2 (7.4) | 73.4 (6.4) | 74.1 (7.6) | 75.0 (7.2) |
| Women, n(%) | 112 | 39 | 56 | 9 | 4 | 4 |
| (50.5%) | (46.4%) | (57.1%) | (37.5%) | (44.4%) | (57.1%) | |
| APOE-ε4 carriershp, n(%) a | 99 (44.6%) | 18 (21.4%) | 56 (57.1%) | 15 (62.5%) | 6 (66.7%) | 4 (57.1%) |
| Years of education | 16.3 (2.5) | 16.5 (2.3) | 16.5 (2.4) | 14.9 (2.8) | 14.7 (2.6) | 17.7 (2.2) |
| Amyloid-PET, Centiloids | 44.0 (41.2) | 7.6 (11.2) | 57.7 (33.3) | 83.6 (23.7) | 119 (38.3) | 57.9 (46.8) |
| Tau-PET, SUVR b | 1.24 (0.22) | 1.13 (0.08) | 1.22 (0.13) | 1.51 (0.38) | 1.72 (0.25) | 1.23 (0.12) |
| Cortical thickness, mm | 2.52 (0.16) | 2.59 (0.12) | 2.53 (0.14) | 2.39 (0.17) | 2.29 (0.15) | 2.35 (0.19) |
| CSF NfL c | 1000 (578) | 740 (313) | 1010 (489) | 1660 (974) | 1360 (404) | 1230 (569) |
| Global cognitive composite, z-score d | 0.44 (1.11) | −0.01 (0.72) | 0.36 (0.75) | 2.01 (0.96) | 3.86 (2.36) | 1.12 (1.40) |
| Progressed to CDR≥0.5e | 41 (18.5%) | 8 (9.5%) | 33 (33.7%) | - | - | - |
| Progressed to CDR≥1f | 30 (14.5%) | 0 (0%) | 14 (14.3%) | 16 (66.7%) | - | - |
, 1 participant missing;
, 3 participants missing;
, 5 participants missing;
, 2 participants missing;
, 4 participants missing;
, 8 participants missing.
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; ADD+, Alzheimer’s disease dementia amyloid positive; CU−, cognitively unimpaired amyloid negative; CU+, cognitively unimpaired amyloid positive; CSF, cerebrospinal fluid; MCI, mild cognitive impairment amyloid positive; mPACC, modified preclinical Alzheimer’s cognitive composite; nonAD, non-Alzheimer’s related disease; PET, positron emission tomography; ROI, region of interest; SD, standard deviation.